# Cara Therapeutics Inc. (CARA)

Source: https://www.quantisnow.com/company/CARA
Generated: 2026-11-19T18:10:07.395Z

- Ticker: CARA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: caratherapeutics.com

## About

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

## Latest CARA news and filings

- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-alibhai-imran-5995135)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-research-development-larson-jeffrey-5995134)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-principal-accounting-officer-obrien-stephen-5995133)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by VP, Chem, Mfg and Ctrls Chen Yixin](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-chem-mfg-and-ctrls-5995132)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-kauh-john-5995131)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Shiff Susan Ph.D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-shiff-susan-phd-5995130)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-conn-avi-5995128)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Smith Cynthia](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-smith-cynthia-5995127)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Wirk Shaheen](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wirk-shaheen-5995126)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Shah Sujal](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-shah-sujal-5995125)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Wyzga Michael S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wyzga-michael-s-5995123)
- 2025-04-21 21:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Hall Wallace L Jr](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hall-wallace-l-jr-5995122)
- 2025-04-17 22:50 UTC [SEC Form 4] [Director Hall Wallace L Jr acquired 246,756 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-hall-wallace-l-jr-acquired-246756-shares-sec-form-5993079)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Director Wyzga Michael S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wyzga-michael-s-5993078)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-principal-accounting-officer-obrien-stephen-5993076)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-kauh-john-5993075)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-research-development-larson-jeffrey-5993074)
- 2025-04-17 22:50 UTC [SEC Form 4] [Director Wirk Shaheen was granted 4,191 shares and acquired 439,194 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-wirk-shaheen-was-granted-4191-shares-and-acquired-439194-5993073)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Director Shah Sujal](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-shah-sujal-5993072)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-conn-avi-5993071)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by VP, Chem, Mfg and Ctrls Chen Yixin](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-chem-mfg-and-ctrls-5993070)
- 2025-04-17 22:50 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-alibhai-imran-5993069)
- 2025-04-17 22:30 UTC [SEC Form 3] [SEC Form 3 filed by new insider O'Brien Stephen Paul](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-obrien-stephen-paul-5993052)
- 2025-04-17 22:28 UTC [SEC Form 3] [SEC Form 3 filed by new insider Wyzga Michael S](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-wyzga-michael-s-5993047)
- 2025-04-17 22:26 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hall Wallace L Jr](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hall-wallace-l-5993043)
- 2025-04-17 22:24 UTC [SEC Form 3] [SEC Form 3 filed by new insider Wirk Shaheen](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-wirk-shaheen-5993041)
- 2025-04-17 22:22 UTC [SEC Form 3] [SEC Form 3 filed by new insider Conn Avi Daniel](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-conn-avi-daniel-5993039)
- 2025-04-17 22:19 UTC [SEC Form 3] [SEC Form 3 filed by new insider Shah Sujal](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-shah-sujal-5993036)
- 2025-04-17 22:16 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kauh John Saewook M.D.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kauh-john-saewook-5993031)
- 2025-04-17 22:13 UTC [SEC Form 3] [SEC Form 3 filed by new insider Alibhai Imran Nizamudin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-alibhai-imran-nizamudin-5993027)
- 2025-04-17 22:11 UTC [SEC Form 3] [SEC Form 3 filed by new insider Smith Cynthia](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-smith-cynthia-5993023)
- 2025-04-17 22:08 UTC [SEC Form 3] [SEC Form 3 filed by new insider Chen Yixin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-chen-yixin-5993018)
- 2025-04-17 22:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Larson Jeffrey Leroy](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-larson-jeffrey-leroy-5993012)
- 2025-04-15 20:06 UTC [SEC Form 8-K] [Cara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure, Other Events](https://www.quantisnow.com/insight/cara-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-5988475)
- 2025-04-14 15:50 UTC [Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics](https://www.quantisnow.com/insight/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-5986595)
- 2025-04-11 20:16 UTC [SEC Form 8-K] [Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cara-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-5985618)
- 2025-04-01 20:30 UTC [SEC Form 8-K] [Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cara-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-5969946)
- 2025-03-24 20:30 UTC [SEC Form 425] [SEC Form 425 filed by Cara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-cara-therapeutics-inc-5957830)
- 2025-03-24 20:30 UTC [SEC Form 8-K] [Cara Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/cara-therapeutics-inc-filed-sec-form-8-k-other-events-5957828)
- 2025-03-11 20:10 UTC [SEC Form 10-K] [SEC Form 10-K filed by Cara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-cara-therapeutics-inc-5938246)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CARA
- Earnings history: https://www.quantisnow.com/earnings/CARA
- Dividend history: https://www.quantisnow.com/dividends/CARA
- Insider transactions: https://www.quantisnow.com/insiders/CARA
- Options chain: https://www.quantisnow.com/options/CARA
- SEC 8-K filings only: https://www.quantisnow.com/company/CARA/8-k
- RSS and alerts for CARA: https://www.quantisnow.com/docs/rss-feeds.md
